Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2019-10-28
- Target Recruit Count
- 70
- Registration Number
- NCT03440788
- Locations
- 🇷🇺
Almazov National Medical Research Centre, Saint Petersburg, Russian Federation
🇷🇺Tula Regional Clinical Hospital, Tula, Russian Federation
🇷🇺Republican Clinical Oncology Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
- Conditions
- Primary Cutaneous Anaplastic Large Cell LymphomaStage III Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage I Cutaneous T-Cell Non-Hodgkin LymphomaLymphomatoid PapulosisStage IV Cutaneous T-Cell Non-Hodgkin LymphomaStage II Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- John Reneau
- Target Recruit Count
- 26
- Registration Number
- NCT03409432
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03373305
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2020-12-10
- Target Recruit Count
- 37
- Registration Number
- NCT03356054
- Locations
- 🇳🇱
NL-Rotterdam-ERASMUSMC, Rotterdam, Netherlands
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT03264131
- Locations
- 🇺🇸
South Broward/Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 82
- Registration Number
- NCT03233347
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.
- Conditions
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Imagine Institute
- Target Recruit Count
- 14
- Registration Number
- NCT03217643
- Locations
- 🇫🇷
Hopital Necker - Enfants malades, Paris, France
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03205891
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03198689
- Locations
- 🇨🇦
Rheumatology Clinic, St. Joseph's Health Care, London, Ontario, Canada
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 20
- Registration Number
- NCT03187210
- Locations
- 🇨🇭
Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.